MX2022006663A - Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este. - Google Patents
Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.Info
- Publication number
- MX2022006663A MX2022006663A MX2022006663A MX2022006663A MX2022006663A MX 2022006663 A MX2022006663 A MX 2022006663A MX 2022006663 A MX2022006663 A MX 2022006663A MX 2022006663 A MX2022006663 A MX 2022006663A MX 2022006663 A MX2022006663 A MX 2022006663A
- Authority
- MX
- Mexico
- Prior art keywords
- heterocyclic compound
- preparation
- compound containing
- containing oxygen
- oxygen
- Prior art date
Links
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title abstract 4
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 4
- 229910052760 oxygen Inorganic materials 0.000 title abstract 4
- 239000001301 oxygen Substances 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000155 isotopic effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se divulga un compuesto heterocíclico que contiene oxígeno, un método de preparación de este y el uso de este. La presente divulgación proporciona un compuesto heterocíclico que contiene oxígeno representado por la fórmula I, una sal farmacéuticamente aceptable de este, un estereoisómero de este, un tautómero de este o un compuesto isotópico de este. Cabe esperar que el compuesto heterocíclico que contiene oxígeno pueda tratar y/o prevenir diversas enfermedades mediadas por Ras. (ver Fórmula).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911212840 | 2019-12-02 | ||
| CN202010368798 | 2020-04-29 | ||
| CN202011077052.0A CN112979664B (zh) | 2019-12-02 | 2020-10-10 | 一种含氧杂环化合物、其制备方法及应用 |
| PCT/CN2020/122335 WO2021109737A1 (zh) | 2019-12-02 | 2020-10-21 | 一种含氧杂环化合物、其制备方法及应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006663A true MX2022006663A (es) | 2022-07-05 |
Family
ID=76221416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006663A MX2022006663A (es) | 2019-12-02 | 2020-10-21 | Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220315598A1 (es) |
| EP (1) | EP4015520B1 (es) |
| JP (1) | JP7480298B2 (es) |
| KR (1) | KR20220136349A (es) |
| AU (1) | AU2020395397A1 (es) |
| BR (1) | BR112022010254A2 (es) |
| CA (1) | CA3163218A1 (es) |
| MX (1) | MX2022006663A (es) |
| WO (1) | WO2021109737A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2020055760A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| KR102871791B1 (ko) | 2018-09-10 | 2025-10-15 | 미라티 테라퓨틱스, 인크. | 병용 요법 |
| SI3849537T1 (sl) | 2018-09-10 | 2025-03-31 | Mirati Therapeutics, Inc. | Kombinirane terapije |
| CA3111980A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3871673B1 (en) | 2018-10-26 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | Novel indazole compound or salt thereof |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| JP7592601B2 (ja) | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| AU2020337938B2 (en) | 2019-08-29 | 2025-09-25 | Array Biopharma Inc. | KRas G12D inhibitors |
| JP2022548791A (ja) | 2019-09-24 | 2022-11-21 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| MX2022005053A (es) | 2019-10-28 | 2022-05-18 | Merck Sharp & Dohme Llc | Inhibidores de peque?as moleculas de mutante g12c de kras. |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| AU2020405170A1 (en) | 2019-12-20 | 2022-06-30 | Mirati Therapeutics, Inc. | SOS1 inhibitors |
| WO2021180181A1 (zh) | 2020-03-12 | 2021-09-16 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| AU2021340716A1 (en) | 2020-09-11 | 2023-03-30 | Mirati Therapeutics, Inc. | Crystalline forms of a KRas G12C inhibitor |
| US20220112204A1 (en) * | 2020-10-14 | 2022-04-14 | Accutar Biotechnology Inc. | Substituted dihydropyranopyrimidine compounds as kras inhibitors |
| US12398154B2 (en) | 2020-12-15 | 2025-08-26 | Mirati Therapeutics, Inc. | Azaquinazoline pan-KRas inhibitors |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| MX2023009037A (es) * | 2021-02-01 | 2023-08-10 | Medshine Discovery Inc | Compuesto de pirimidopirano. |
| WO2022187527A1 (en) * | 2021-03-05 | 2022-09-09 | Nikang Therapeutics, Inc | Quinazoline nitrile derivatives as kras inhibitors |
| CN115385923A (zh) * | 2021-05-24 | 2022-11-25 | 上海璎黎药业有限公司 | 一种含氧杂环化合物的晶型、其制备方法及应用 |
| WO2022251576A1 (en) * | 2021-05-28 | 2022-12-01 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| AU2022320304A1 (en) | 2021-07-27 | 2024-02-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| EP4511372A1 (en) * | 2022-04-18 | 2025-02-26 | Mirati Therapeutics, Inc. | Processes and intermediates for synthesis of adagrasib |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| TW202529768A (zh) | 2023-09-29 | 2025-08-01 | 大陸商德昇濟醫藥（無錫）有限公司 | 癌症治療的療法 |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010064705A1 (ja) * | 2008-12-05 | 2010-06-10 | 大日本住友製薬株式会社 | Ｈ４受容体アンタゴニスト作用を有する新規７位置換ジヒドロピラノピリミジン誘導体 |
| JP2012531422A (ja) * | 2009-06-24 | 2012-12-10 | ジェネンテック， インコーポレイテッド | オキソ−複素環縮合ピリミジン化合物、組成物及び使用方法 |
| US10125144B2 (en) * | 2013-10-07 | 2018-11-13 | Kadmon Corporation, Llc | Rho kinase inhibitors |
| BR112017021869A2 (pt) * | 2015-04-10 | 2018-12-11 | Araxes Pharma Llc | compostos quinazolina substituídos e métodos de uso dos mesmos |
| WO2016210330A1 (en) * | 2015-06-26 | 2016-12-29 | Kadmon Corporation, Llc | Glucose uptake inhibitors |
| KR101777475B1 (ko) * | 2015-12-08 | 2017-09-11 | 에스티팜 주식회사 | 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도 |
| JP7039489B2 (ja) * | 2016-05-18 | 2022-03-22 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| US10745385B2 (en) * | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| CA3082579A1 (en) * | 2017-11-15 | 2019-05-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| TW201942115A (zh) * | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
| TW201942116A (zh) | 2018-02-09 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌劑之四氫喹唑啉衍生物 |
| JP7720698B2 (ja) * | 2018-04-04 | 2025-08-08 | アルビナス・オペレーションズ・インコーポレイテッド | タンパク質分解の調節因子および関連する使用方法 |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| WO2021180181A1 (zh) * | 2020-03-12 | 2021-09-16 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
-
2020
- 2020-10-21 CA CA3163218A patent/CA3163218A1/en active Pending
- 2020-10-21 AU AU2020395397A patent/AU2020395397A1/en not_active Abandoned
- 2020-10-21 BR BR112022010254A patent/BR112022010254A2/pt not_active IP Right Cessation
- 2020-10-21 US US17/767,046 patent/US20220315598A1/en active Pending
- 2020-10-21 JP JP2022532809A patent/JP7480298B2/ja active Active
- 2020-10-21 KR KR1020227022934A patent/KR20220136349A/ko not_active Withdrawn
- 2020-10-21 WO PCT/CN2020/122335 patent/WO2021109737A1/zh not_active Ceased
- 2020-10-21 MX MX2022006663A patent/MX2022006663A/es unknown
- 2020-10-21 EP EP20895574.0A patent/EP4015520B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4015520A1 (en) | 2022-06-22 |
| BR112022010254A2 (pt) | 2022-09-06 |
| EP4015520B1 (en) | 2025-02-19 |
| WO2021109737A1 (zh) | 2021-06-10 |
| JP2023504178A (ja) | 2023-02-01 |
| AU2020395397A1 (en) | 2022-06-09 |
| CA3163218A1 (en) | 2021-06-10 |
| KR20220136349A (ko) | 2022-10-07 |
| JP7480298B2 (ja) | 2024-05-09 |
| US20220315598A1 (en) | 2022-10-06 |
| EP4015520A4 (en) | 2023-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006663A (es) | Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este. | |
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| GEP20237568B (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| GEAP202215535A (en) | Compounds | |
| MX2023010326A (es) | Inhibidores de atf6 y sus usos. | |
| SA519401336B1 (ar) | تركيبة صيدلية | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| MX373935B (es) | Compuestos antiproliferativos y métodos de uso de los mismos. | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| MX2023000418A (es) | Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia. | |
| MX2024014861A (es) | Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo | |
| GEP20237470B (en) | Magl inhibitors | |
| MY195194A (en) | Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| GEAP202115281A (en) | Spirocycle compounds and methods of making and using same | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| WO2018209363A3 (en) | PROPIONIC ACID DERIVATIVES AND ASSOCIATED METHODS OF USE | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| SV2018005702A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| BR112018015629A2 (pt) | ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla? |